SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 72 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $901,000 | +11.1% | 102,631 | -5.5% | 0.02% | +25.0% |
Q3 2019 | $811,000 | +49.1% | 108,576 | +86.0% | 0.02% | +66.7% |
Q2 2019 | $544,000 | -24.0% | 58,385 | -57.2% | 0.01% | -25.0% |
Q1 2019 | $716,000 | +76.4% | 136,423 | +49.4% | 0.02% | +45.5% |
Q4 2018 | $406,000 | +16.3% | 91,339 | +81.5% | 0.01% | +57.1% |
Q2 2018 | $349,000 | -80.0% | 50,332 | -58.9% | 0.01% | -81.1% |
Q1 2018 | $1,744,000 | +48.8% | 122,567 | -9.3% | 0.04% | +48.0% |
Q4 2017 | $1,172,000 | +104.2% | 135,133 | +179.0% | 0.02% | +127.3% |
Q3 2017 | $574,000 | +48.3% | 48,442 | +75.0% | 0.01% | +37.5% |
Q2 2017 | $387,000 | – | 27,689 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aisling Capital Management LP | 1,025,000 | $24,631,000 | 16.36% |
Kynam Capital Management, LP | 2,272,915 | $54,618,000 | 11.51% |
Frazier Life Sciences Management, L.P. | 3,412,838 | $82,010,000 | 6.32% |
Foresite Capital Management IV, LLC | 690,000 | $16,581,000 | 5.33% |
Paradigm Biocapital Advisors LP | 1,085,142 | $26,076,000 | 3.48% |
ACUTA CAPITAL PARTNERS, LLC | 324,614 | $7,800,000 | 3.36% |
COMMODORE CAPITAL LP | 738,110 | $17,737,000 | 2.85% |
SPHERA FUNDS MANAGEMENT LTD. | 822,696 | $19,769,000 | 2.74% |
Avidity Partners Management LP | 5,586,900 | $134,253,000 | 2.73% |
HealthCor Management, L.P. | 859,240 | $20,648,000 | 2.58% |